Editas Medicine

About Editas Medicine

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.


YEAR FOUNDED:

2013

LEADERSHIP:

Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu

CEO: Karine Bosley

CFO: Andrew Hack

COO: Alexandra Glucksmann

CTO: Vic Myer

JOBS:

Please click here for Editas Medicine job opportunities.

FOLLOW EDITAS MEDICINE:

Tweets by Editas Medicine